Compare DexCom, Inc. (DXCM) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Hilton Hotels Corporation Common Stock — how do they compare? DexCom, Inc. trades at $84.03 (market cap $31.86B), while Hilton Hotels Corporation Common Stock trades at $327.3 (market cap $72.76B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 2.3× DexCom, Inc.'s market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Hilton Hotels Corporation Common Stock for 138 Days on average.
| DXCM | HLT | |
|---|---|---|
Market Cap | $31.86B | $72.76B |
Volume | 3,607,070 | 1,148,634 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $350.22 |
52-Week Low | $54.84 | $256.96 |
Typical Hold Time | 62 Days | 138 Days |
Enterprise Value | $31.32B | $85.78B |
Dividend Yield | — | 0.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Hilton Worldwide (HLT) trades at $320.5, down 0.65% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $348.11. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results expected soon. Revenue has grown steadily from $8.8B in 2022 to $12.04B in 2025, though net income margins have fluctuated. Recent news highlights institutional buying and positive travel trends for 2027.
The outlook for HLT is positive, supported by strong earnings performance, analyst optimism, and growth in travel demand. Key risks include high debt levels, with debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles affecting travel spending. The stock offers potential upside to the consensus target, but investors should monitor debt management and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
